Form4insider filings, from the source

SEC Form 4 · accession 0001581754-26-000006

Latigo Biotherapeutics, Inc. · LTGO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
James B. Tananbaum
Director · 10% Owner
Period of report
Aug 10, 2026
Accepted (ET)
Aug 10, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002056611

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Aug 10, 2026C3,117,664—A3,117,664ISee footnote
Common StockF1,F2Aug 10, 2026C445,320—A3,562,984ISee footnote
Common StockF1,F3Aug 10, 2026C1,125,823—A1,125,823ISee footnote
Common StockF1,F3Aug 10, 2026C742,201—A1,868,024ISee footnote
Common StockF3Aug 10, 2026P140,000$18.00A2,008,024ISee footnote
Common StockF4,F3Aug 10, 2026C195,776—A2,203,800ISee footnote
Common StockF1,F5Aug 10, 2026C3,117,664—A3,117,664ISee footnote
Common StockF1,F5Aug 10, 2026C296,880—A3,414,544ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A-2 Convertible StockF1,F2—Aug 10, 2026C3,117,664D——Common Stock3,117,6640I
Series B Convertible Preferred StockF1,F2—Aug 10, 2026C445,320D——Common Stock445,3200I
Series A-2 Convertible Preferred StockF1,F3—Aug 10, 2026C1,125,823D——Common Stock1,125,8230I
Series B Convertible Preferred StockF1,F3—Aug 10, 2026C742,201D——Common Stock742,2010I
Series A-2 Convertible Preferred StockF1,F5—Aug 10, 2026C3,117,664D——Common Stock3,117,6640I
Series B Convertible Preferred StockF1,F5—Aug 10, 2026C296,880D——Common Stock296,8800I
Convertible Promissory NoteF4,F3—Aug 10, 2026C195,776D——Common Stock195,7760I

Explanation of responses